ArticleOncogene2009
Polo-like kinase 1 phosphorylates and regulates Bcl-x(L) during pironetin-induced apoptosis.
Article in Oncogene, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 39 citations in OpenAlex.
- PLK1 inhibition leads to mitotic arrest and triggers apoptosis in cholangiocarcinoma cells.Oncology letters · 2024Article
- Destabilization of vitelline membrane outer layer protein 1 homolog (VMO1) by C-mannosylation.FEBS open bio · 2023Article
- Tyrosinase suppresses vasculogenic mimicry in human melanoma cells.Oncology letters · 2022Article
- ErbB4-mediated regulation of vasculogenic mimicry capability in breast cancer cells.Cancer science · 2022Article
- Synergistic apoptotic effect of miR-183-5p and Polo-Like kinase 1 inhibitor NMS-P937 in breast cancer cells.Cell death and differentiation · 2022Article
- Involvement of DPY19L3 in Myogenic Differentiation of C2C12 Myoblasts.Molecules (Basel, Switzerland) · 2021Article
- Conformational States of the Cytoprotective Protein Bcl-xL.Biophysical journal · 2020Article
- Revisiting microtubule targeting agents: α-Tubulin and the pironetin binding site as unexplored targets for cancer therapeutics.Bioorganic & medicinal chemistry letters · 2019Review
- Complex karyotype AML displays G2/M signature and hypersensitivity to PLK1 inhibition.Blood advances · 2019Article
- Regulation of apoptosis by an intrinsically disordered region of Bcl-xL.Nature chemical biology · 2018Article
- Review
- Polo-like Kinase 1 as a potential therapeutic target in Diffuse Intrinsic Pontine Glioma.BMC cancer · 2016Article
- JNK1 Inhibition Attenuates Hypoxia-Induced Autophagy and Sensitizes to Chemotherapy.Molecular cancer research : MCR · 2016Article
- Proteomic profiling of small-molecule inhibitors reveals dispensability of MTH1 for cancer cell survival.Scientific reports · 2016Article
- Targeting polo-like kinase 1 in acute myeloid leukemia.Therapeutic advances in hematology · 2015Review
- Identification of rictor as a novel substrate of Polo-like kinase 1.Cell cycle (Georgetown, Tex.) · 2015Article
- Volasertib for AML: clinical use and patient consideration.OncoTargets and therapy · 2015Review
- Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy.Leukemia · 2015Review
- Phospho-Bcl-xL(Ser62) influences spindle assembly and chromosome segregation during mitosis.Cell cycle (Georgetown, Tex.) · 2014Article
- Gene mutations and molecularly targeted therapies in acute myeloid leukemia.American journal of blood research · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bcl-x(L), an anti-apoptotic Bcl-2 family member protein, contributes to the resistance against chemotherapies such as tubulin-binder treatment in many human tumors. Although Bcl-x(L) is phosphorylated after tubulin-binder treatment, the role of the phosphorylation and its responsible kinase(s) are poorly understood. Here, we identified Plk1 (polo-like kinase 1) as a Bcl-x(L) kinase. Same location of Bcl-x(L) and Plk1 was revealed by immunocytochemical analyses at M-phase in situ. Plk1 phosphorylates Bcl-x(L) in vitro, and we identified Plk1 phosphorylation sites in Bcl-x(L). When all of these phosphorylation sites were substituted to alanines, the anti-apoptotic activity of the Bcl-x(L) mutant against the apoptosis induced by pironetin, but not against ultraviolet-induced apoptosis, was increased. These observations suggest that Plk1 is a regulator of Bcl-x(L) phosphorylation and controls the anti-apoptotic activity of Bcl-x(L) during pironetin-induced apoptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.